Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with breast, colorectal or gastric cancer under fed condition: A multicentric, randomized, open-label, single-dose, two-period, two-way crossover clinical trial
-
Published:2023-03
Issue:
Volume:182
Page:106373
-
ISSN:0928-0987
-
Container-title:European Journal of Pharmaceutical Sciences
-
language:en
-
Short-container-title:European Journal of Pharmaceutical Sciences
Author:
Ma Haiping,
Zhao Naping,
Luo Suxia,
Zhang Yanqiao,
Yuan Zhijun,
Sun Hao,
Gao Shen,
Zhan Xianbao,
Zhang LiORCID
Subject
Pharmaceutical Science
Reference30 articles.
1. Bio-international 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies;Blume;J. Pharm. Sci.,1993
2. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients;Cassidy;Cancer Chemother. Pharmacol.,1999
3. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer;Chachad;Cancer Chemother. Pharmacol.,2013
4. Cope, J.U., 2016. Presentation: Xeloda (Capecitabine). https://www.fda.gov/media/96938/download (accessed 25 March 2022).
5. Plasma disposition of capecitabine and its metabolites 5’DFCR and 5’DFUR in a standard and dose-intensified monotherapy regimen;Czejka;Cancer Chemother. Pharmacol.,2011
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献